Immunogenicity and safety of a severe acute respiratory syndrome coronavirus 2 inactivated vaccine in healthy adults: randomized, double-blind, and placebo-controlled phase 1 and phase 2 clinical trials-Reference-Cited by-同舟云学术

Immunogenicity and safety of a severe acute respiratory syndrome coronavirus 2 inactivated vaccine in healthy adults: randomized, double-blind, and placebo-controlled phase 1 and phase 2 clinical trials

Published:2021-04-28 Issue:11 Volume:134 Page:1289-1298
ISSN:0366-6999
Container-title:Chinese Medical Journal
language:en
Short-container-title:

Author:

Pan Hong-Xing,Liu Jian-Kai,Huang Bao-Ying,Li Gui-Fan,Chang Xian-Yun,Liu Ya-Fei,Wang Wen-Ling,Chu Kai,Hu Jia-Lei,Li Jing-Xin,Zhu Dan-Dan,Wu Jing-Liang,Xu Xiao-Yu,Zhang Li,Wang Meng,Tan Wen-Jie,Huang Wei-Jin,Zhu Feng-Cai

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Medicine,General Medicine

Reference17 articles.

1. A novel coronavirus from patients with pneumonia in China, 2019;Zhu;N Engl J Med,2020

2. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial;Zhu;Lancet,2020

3. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial;Zhu;Lancet,2020

4. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials;Xia;JAMA,2020

5. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial;Zhang;Lancet Infect Dis,2021

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety, immunogenicity and protection of heterologous boost with an aerosolised Ad5-nCoV after two-dose inactivated COVID-19 vaccines in adults: a multicentre, open-label phase 3 trial;The Lancet Infectious Diseases;2023-10

2. Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine KCONVAC in Chinese Children: Randomized, Double-blind, Placebo-controlled Phase 1 and 2 Trials;Pediatric Infectious Disease Journal;2023-09-04

3. Comparison of Antibody Responses After CoronaVac and BNT162b2 Vaccines in Healthcare Workers;Indian Journal of Microbiology;2023-09

4. COVID-19 Vaccines over Three Years after the Outbreak of the COVID-19 Epidemic;Viruses;2023-08-23

5. Comparative Immunogenicity, Safety and Efficacy Profiles of four COVID-19 Vaccine types in healthy adults: Systematic Review cum Meta-analysis of Clinical Trial data;2023-08-12